

Development and Characterization of a Potent Tumor Necrosis Factor-Alpha Blocking Agent

Aida Jameei*, Deepesh Nagarajan*, Mohsen Sarikhani#, Nagasuma Chandra* and Anjali A. Karande*

*Department of Biochemistry, # Department of Microbiology and Cell Biology,

Abstract

Tumor necrosis factor- α (TNF α), one of the major pro-inflammatory cytokines, plays a key role in an effective immune response. However, the chronic presence of TNF α can lead to several inflammatory disorders like rheumatoid arthritis, psoriasis, Crohn's disease etc. Inhibition of TNF α by pharmacological inhibitors or antibodies has proven to be effective in palliative treatment to some extent. The aim of this study was to develop an anti-TNF α antibody which may be used as a therapeutic option to inhibit TNF α -mediated cytotoxicity. We characterized several hybridoma clones secreting monoclonal antibodies (mAbs) to human-TNF α . Four mAbs rescued L929 fibroblast cells from TNF α -triggered cell death and one of these, namely C8 was found to have the highest affinity. To gain insights into the mechanism by which mAb C8 inhibits human TNF α -mediated toxicity, the epitope corresponding to the mAb was delineated. The antigenic determinant was found to comprise of the stretch of amino acids 99-120, of which, 102-104 (QRE) form the core epitope. The observation was supported by bioinformatics analyses of an antigen-antibody complex model. In addition, the binding affinity of mAb C8 to TNF α was found to be comparable with that of Infliximab which is a commercially available anti TNF α mAb.

1. Introduction

TNF is a pro-inflammatory cytokine having pleiotropic effects on immune cells and plays an indispensable role in inflammation, cell differentiation, cell proliferation, apoptosis and cell metabolism [1, 2].

There are two types of TNF, TNF α and TNF β , both of which are cytotoxic [3],[4]. They are sequentially and structurally related and compete with each other for binding to their receptors [5]. Soluble TNF α exerts a broad range of biological activities on interaction with two specific receptors, TNF α receptor-type 1 (TNFR1 or p55) and TNF α receptor-type 2 (TNFR2 or p75). TNFR1, expressed on almost all cell types, plays a major role in triggering the TNF α signaling pathways. TNFR2 expression on the other hand is mostly limited to the cells of the immune system, nerve cells and endothelial cells, under normal physiological conditions [6-8]. Upon binding to receptors, TNF α promotes a series of intracellular signaling cascades such as, activation of transcription factor NF κ B, p38 mitogen activated protein kinase (p38MAPK), c-Jun N-terminal kinase (JNK) extracellular signal regulated kinase (ERK) [8, 9].

Although TNF α plays an essential role in an effective immune response, its' unrestricted production may lead to several inflammatory disorders. Inhibition of TNF α by pharmacological agents has proven to be effective in palliative treatment [10, 11].

In the study described in this manuscript, we developed an anti-human TNF α mAb namely C8 which can neutralize human-TNF α activity. Further, using truncation and mutation analysis, we mapped the TNF α binding sites of the mAb, which was supported by docking studies using sequenced variable regions of heavy and light chain of the antibody.

A study of mAb C8 and Infliximab (a commercialized anti-TNF α antibody), demonstrated that both antibodies have comparable affinities as well TNF α neutralizing efficiency.

Methods

Animal and Cell lines

All the animal experiments reviewed and approved by Institutional Animal Ethics Committee (IAEC) of Indian Institute of Science, CAF/Ethics/184/2010 dated June 16, 2010. L929 mouse fibroblast cells were maintained as monolayer cultures in Dulbecco's modified eagles medium (DMEM) and passaged every 2-3 days using 0.25% trypsin-EDTA. Hybridoma cells were cultured in Iscove's modified Dulbecco's medium (IMDM). Both media were supplemented with 10% fetal bovine serum (FBS), 1mM Glutamax (Gibco) and antibiotics. IMDM was supplemented also with 50 μ M β -mercaptoethanol. All cultures were maintained at 37°C in a humidified incubator with 5% CO₂.

Expression and purification of His-tagged human-TNF α and mouse-TNF α

E. coli BL21 (DE3) strain cells were transformed with the pET15b vector containing the human-TNF α gene and pET28a vector containing the mouse-TNF α gene. Then cells were induced with 1 mM IPTG and were incubated at 30°C for 8 hr in an incubator shaker, at 200 rpm for the expression of each respective protein; the cells were harvested by centrifugation at 6000 rpm for 20 min at 4°C. The cell pellet obtained was resuspended with 50 mM Tris-HCl, pH 8.0 containing 150 mM NaCl (TBS), sonicated (sonication conditions: 4°C, ampt 30%, 30 min) and the soluble proteins were separated by centrifugation at 13,000 rpm for 30 min at 4°C. The supernatant (soluble protein) was loaded on the Ni-NTA column. Unbound proteins were washed away with TBS containing 30 mM imidazole and the bound protein was eluted with 300 mM imidazole in TBS. After elution, the protein was dialyzed against PBS (50 mM phosphate buffer pH, 7.4, containing 150 mM NaCl). The concentration of proteins was estimated using Bradford method.

Generation of monoclonal antibodies against human-TNF α

Eight weeks old female BALB/c mice were immunized by subcutaneous injection with 5 μ g of human-TNF α protein in phosphate-buffered saline PBS emulsified with Freund's complete adjuvant and boosted twice with 5 μ g of the same antigen in Freund's incomplete adjuvant at 21 days interval. The animals were rested for a month. Three days prior to sacrificing, the mice were administrated intraperitoneally with 5 μ g of antigen in PBS. The splenocytes were collected and fused with mouse myeloma cells SP2/0 (ratio 5:1) using PEG 4000 (Merck, Rahway, NJ). The fused cells were plated in IMDM supplemented with HAT (10 mM hypoxanthine, 40 μ M aminopterin and 1.6 mM thymidine), 20% (v/v) FBS and 50 μ M Mercaptoethanol. They were examined for secretion of anti-TNF α specific antibodies using ELISA after 10 days. The positive clones were subcloned to monoclonality by limiting dilution method. MABs were purified by protein A (Sigma-Aldrich, St. Louis MO).

Enzyme linked immunosorbent assay (ELISA)

ELISA plates were coated with protein in 100 μ l PBS (50 mM phosphate buffer pH, 7.4, containing 150 mM NaCl), overnight at room temperature (RT). After blocking the unoccupied sites of the wells with 0.5% gelatin in PBS for 1 hr at RT, hybridoma culture supernatants or purified antibodies were added and incubated for 2 hr. Plates were washed with PBST (T =Tween 20, at 0.05%) followed by PBS and incubated with 100 μ l of secondary antibody conjugated to horse radish peroxidase (HRP) for 45 min. After washing the plates, 100 μ l of substrate (0.03 % H₂O₂ in citrate phosphate buffer, pH 5.5 and the chromogen 3, 3', 5, 5'-tetra methyl benzidine (60 μ g/ml)) was added. The reaction was stopped with 50 μ l of 1M H₂SO₄ and absorbance was measured at 450 nm using an ELISA microplate reader.

To determine comparative affinities of the mAbs, ELISA was performed as above, but after the incubation with the mAbs, ammonium thiocyanate (NH₄SCN) was added at varying concentrations (0.5, 1.0, 2.0, 3.0, 4.0 and 6.0 M) in 0.1 M sodium phosphate buffer pH 6.0. The plates were incubated for 15 min at RT prior to washing with PBS, followed by blocking with 0.5% BSA in PBS for 1 hr at RT, before addition of the secondary antibody conjugate. The rest of the procedure followed was as mentioned above.

For obtaining antigen and antibody dilution curves, four concentrations (500, 250, 125, 62.5 ng/well in 100 µl PBS) of hTNFα were coated in ELISA plate, blocked with 0.5% gelatin in PBS, 100 µl serially double diluted hybridoma culture supernatant was added ranging from undiluted to 1:1024 and incubated for 2 hr at RT. The remaining steps were carried out in the same way as mentioned above.

For Inhibition ELISA, 500 ng antigen/well was coated in ELISA plate overnight at RT. After blocking the plates with 0.5% gelatin in PBS for 1 hr at RT, varying concentrations of the antigen (5 µg serially double diluted to 0.0097 µg) was added in 50 µl, followed immediately with 50 µl of appropriately diluted (exhibiting a binding of ~85% of the B_{max}) anti-TNFα antibodies and incubated for 2 hr at RT. The remaining steps were carried out in the same way as mentioned above.

Western blot analysis of mAb C8

HumanTNFα or its fragments, 1 µg each were electrophoresed on 12.5 % polyacrylamide gel under reducing conditions and transferred to nitrocellulose membrane using a semi-dry electro-transfer apparatus, at 125 mA. The membrane was incubated in blocking solution (5% skimmed milk in PBS) for 2 hr or overnight followed by incubation with the mAb for 2 hr. The membrane was washed with PBST and incubated with the secondary antibody (rabbit α-mouse Ig-HRP) for 45 min and developed using ECL kit (Millipore).

L929 cells were incubated with TNFα for 30 min, then washed with cold PBS 3 times, followed by suspension in lysis Buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X 100, 1mM EDTA, 1mM EGTA, NaVO₃, Sodium Pyrophosphate, Protease Inhibitors). The mixture was vortexed and centrifuged and the protein concentration of the supernatant was estimated. Equal amount of each protein sample was mixed with Laemmli Buffer (2X, BioRad), heated for 5 min at 95°C and resolved by SDS-PAGE followed by overnight transfer to a PVDF membrane (GE, Cat#10600023) at 25v at 4°C. The membrane was blocked with 5% non-fat dried milk in TBST buffer (25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 20). For detection of proteins, blots were incubated with their respective antibodies (anti -JNK, -p-JNK, -β actin) at 4°C overnight. After washing three times with TBST buffer, peroxidase-conjugated secondary antibody (Santa Cruz, 1:10000) was added and incubated at RT for 1 hr. Signals were detected using chemiluminescence substrate solution (Thermofischer # 34080) and analyzed by a GE LAS4000 luminescent image analyzer (Fuji Photo Film).

MTT assay

Viability of cells was checked using MTT 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay. For the assay, L929 fibroblast cells were plated in 48-well flat bottom tissue culture plate at 10000 cells/well in 200 μ l DMEM supplemented with 10% FBS (fetal bovine serum). Cells were allowed to attach overnight and then incubated with different concentrations of hTNF α . Actinomycin-D (2 μ g/ml) was used as positive control. After 48 hr incubation, 20 μ l of MTT solution (5 mg/ml in PBS) was added per well, incubated for 4 hr at 37 $^{\circ}$ C in CO₂ incubator. Formazan crystals formed as a result were dissolved with 100 μ l of DMSO and transferred to a 96-well culture plate and OD was measured in a microplate reader, at 570 nm.

Cloning of mutant constructs of hTNF α gene

Deletion constructs of the hTNF α gene were cloned in pGEX5X2 vector between BamHI and XhoI restriction enzyme sites at the 5' and 3' end respectively. All clones carried an N-terminal GST-tag and were amplified employing the primers listed in Table 1.

Table 1: List of oligonucleotides used for generating the deletion constructs of hTNF α

Name	Sequence (5'→3')	Restriction enzyme site
F1 1-53 FP	TAACCGGGATCCCGGTCAGATCATCTTCTC	BamHI
F1 1-53 RP	TGCTTCCGCTCGAGTCACTCTGATGGCACCAC	XhoI
F2 26-131 FP	TAACCGGGATCCCGCTCCAGTGGCTGAAC	BamHI
F2 26-131 RP	TGCTTCCGCTCGAGTCATCGGTACCCCTTCTCC	XhoI
F3 96-157 FP	TAACCGGGATCCCGCCATCAAGAGCCCCTG	BamHI
F3 96-157 RP	TGCTTCCGCTCGAGTCACAGGGCAATGATC	XhoI
F2 core region 54-93 FP	TAACCGGGATCCCG GTGGTGCCATCAGAG	BamHI
F2 core region 54-93 RP	TGCTTCCGCTCGAGTCACAGGGGCTCTTGATGG	XhoI
F2-F1 72-131 FP	TAACCGGGATCCCGCTCCTCACCCACACC	BamHI
R1 72-107 FP	CCGGGATCCCGCTCCTCACCCACACC	BamHI
R1 72-107 RP	CCGCTCGAGTCACTCTGGGGTCTCCCTCTGG	XhoI
R2 99-131 FP	CCGGGATCCcctgCCAGAGGGAGACCC	BamHI
R2 99-131 RP	CCGCTCGAGTCATCGGTACCCCTTCTCC	XhoI

R3 85-120 FP	CCGGGATCCcCTACCAGACCAGGGTC	BamHI
R3 85-120 RP	CCGCTCGAGTCACAGATAGATGGGCTCATAC	XhoI

The PCR cycle used for the amplification procedure was as follows: initial denaturation - 94 °C, 5 min; denaturation - 94 °C, 1 min; annealing - 55 °C, 45 sec; extension - 72 °C, 1 min; final extension - 72 °C, 10 min. The denaturation, annealing and extension steps were carried out for 30 cycles. The hTNF α cloned in pET15b was used as the template and Deep Vent polymerase was used for amplification of DNA in the PCR reactions. The clones obtained were screened by digestion with restriction enzymes and confirmed by DNA sequencing.

Site-directed mutant genes were generated by quick change primer design method [12]. Sense and anti-sense primers carried the desired site-specific mutation along with a specific restriction enzyme site. The plasmid carrying the wild type hTNF α gene construct was amplified by PCR. The amplified product was subjected to DpnI digestion to digest the methylated plasmid template and *E.coli* DH5 α cells were transformed with the plasmid.

The hTNF α F2 mutant clones, T72 to D; H73 to Y; T89 to E; S71deletion; TH72,73 DY; Q102 to P; R103 to K; E104 to D; R103E104 to KD; R131 to Q; S71 deletion + T 72 to D; S 71 deletion + H73 to Y and Q102R103E104 to PKD were obtained by quick-change primer design method. Phusion High-Fidelity DNA Polymerase was used for carrying out PCR reactions. In a PCR cycle, initial denaturation was carried out at 98°C for 2 min followed by 25 cycles of denaturation at 98 °C for 1 min, annealing for 1 min (at the temperature specified for each clone in the Table 2) and extension at 72 °C for 6 min. The final extension for end-filling was carried out at 72 °C for 10 min (For first 4 cycles, we have prepared reactions with forward or reverse primers separately and then pooled together for another 21 cycles).

All site-directed mutant DNA fragments obtained were cloned in pGEX5X2 vector between BamHI and XhoI restriction enzyme sites. The recombinant plasmids were isolated. The sequence of the clones obtained was verified by sequencing to confirm the presence of the desired mutations. All clones carried an N-terminal GST-tag and were amplified employing the primers listed in Table 2.

Table 2: List of oligonucleotides used for generating the site-directed mutants of hTNF α

Name	Sequence (5'→3')
S71deletion FP	CCAAGGCTGCCCCGACTACGTGCTCC
S71deletion RP	GGAGCACGTAGTCGGGGCAGCCTTGG
T72D FP	CAAGGCTGCCCCCTCCGACCATGTGCTCCTC

T72D RP	GAGGAGCACATGGTCGGAGGGGCAGCCTTG
H73Y FP	GGCTGCCCCCTCCACCTACGTGCTCCTCAC
H73Y RP	GTGAGGAGCACGTAGGTGGAGGGGCAGCC
TH72,73DY FP	GGCTGCCCCCTCCGACTACGTGCTCCTCAC
TH72,73DY RP	GTGAGGAGCACGTAGTCGGAGGGGCAGCC
S71 deletion T72D P	CCAAGGCTGCCCCGACCATGTGCTCC
S71 deletion RP	GGAGCACATGGTCGGGGCAGCCTTGG
S71 deletion H73Y P	CCAAGGCTGCCCCGACCATGTGCTCC
S71 deletion H73Y P	GGAGCACGTAGGTGGGGCAGCCTTGG
T89E FP	CATCGCCGTCTCCTACCAGGAGAGGGTCAACCTCCTCTCTG
T89E RP	CAGAGAGGAGGTTGACCCTCTCCTGGTAGGAGACGGCGATG
Q102P FP	GGGTCTCCCTCGGGCAGGGGCTC
Q102P RP	GAGCCCCTGCCCCGAGGGAGACCC
R103K FP	GGGGTCTCCTTCTGGCAGGGGCTCTTG
R103K RP	CAAGAGCCCCTGCCAGAAGGAGACCCC
E104D FP	CTCTGGGGTATCCCTCTGGCAGGGGCT
E104D RP	AGCCCCTGCCAGAGGGATACCCCAGAG
RE103,104KD FP	CAAGAGCCCCTGCCAGAAGGATACCCCAGAG
RE103,104KD RP	CTCTGGGGTATCCTTCTGGCAGGGGCTCTTG
R131Q FP	GAGAAGGGTGACCAATGACTCGAGCGG
R131Q RP	CCGCTCGAGTCATTGGTCACCCTTCTC

cDNA was prepared from total RNA isolated from mAb C8 hybridoma cells using oligo (dT) primers. The variable regions of the heavy (VH) and light chain (VL) were amplified by PCR using the cDNA as template and the respective universal primers listed in Table 3. The VH and VL DNA fragments (~300 bp) were generated using Deep Vent polymerase, cloned into the pGEMT vector system and screened by digestion with the restriction enzymes NcoI and NdeI. The DNA was sequenced.

Table 3: List of oligonucleotides used for generating mAb C8 variable regions of heavy (VH) and light (VL)

Name	Sequence (5'→3')	Annealing temperature PCR (°C)
V _H FP	TGAGGAGACGGTGACCGTGGTCCCTTGGCCCCA	54
V _H RP	AGGTGAAACTGCAGGAGTCAGG	54
V _L FP	GTTAGATCTCCAGCTTGGTCC	50
V _L RP	GACATTCAGCTGACCCAGTCTCCA	50

Expression and purification of hTNF α recombinant proteins

All recombinant hTNF α overlapping truncated and mutant forms of hTNF α F2 constructs in pGEX5X2 vector have an N-terminal GST-tag. *E. coli* BL21 (DE3) cells were transformed with each plasmid and were induced to express respective protein with 1 mM IPTG for hTNF α F1 and F3 for 4 hr at 30 °C and 0.1mM IPTG for hTNF α F2 and F2-mutants for 14 hr at 20 °C in an incubator shaker, at 200 rpm. The cells were harvested with centrifugation and the pellet obtained was resuspended and sonicated in lysis buffer (50 mM Tris, pH 8, 150 mM NaCl and 1 mM PMSF) containing lysozyme for 20 min using 5 sec On and Off pulses and then spun at 13000 rpm for 30 min at 4 °C. The supernatant was passed through pre-equilibrated column (using wash buffer: 20 mM Tris, pH 7.5, 150 mM NaCl and 0.1% Triton X-100), Unbound proteins were washed away with wash buffer and the GST-fusion protein was eluted with 10 mM reduced glutathione in 50 mM Tris, pH 8. After elution, the protein was dialyzed against PBS. The concentration of proteins was estimated using Bradford method.

Bioinformatics Analysis

To determine the amino acid sequence of the variable regions of heavy (VH) and light (VL) chains of mAb C8, the amino acid sequence derived from the obtained DNA sequences were utilized for hTNF α -C8 docking study. hTNF α - mAb C8 modelling was performed using the SWISS-MODEL server [13] and superposed onto PDB ID 4g3y using Mustang [14]. All structural images were analysed and visualized using the open-source PyMOL software (www.pymol.org). Local protein-protein docking and Energy minimization for both WT TNF-Ab as well as mutated TNF-Ab complexes was performed using Rosetta [15].

Results

The human TNF α (hTNF α) gene was cloned in a His-tag expression vector, expressed and purified using Ni-NTA affinity chromatography and the expected protein size was seen in SDS-PAGE gel stained with Coomassie brilliant blue. Mass spectrometry analysis confirmed the molecular size of the purified hTNF α (Figure S1 A and B).


Binding of anti -TNF α monoclonal antibodies to TNF α

To screen the binding of the mAbs to hTNF α , indirect ELISA was carried out. Thirteen clones were found to bind specifically to hTNF α (Figure S1C). In spite of more than 70% sequence identity between human and mouse TNF α (mTNF α), only one out of the 13 mAbs, namely C12, bound also to mouse-TNF α (Figure S1D)

In order to identify high affinity antibodies, different concentrations of immobilized hTNF α antigen were incubated with different dilutions of the anti-TNF α mAbs. While all the mAbs bound to 500 ng h-TNF α , except mAbs C8 and C12, none bound significantly to lower concentrations of the immobilized antigen. In case of the mAb C8, there was no apparent difference in the binding of the mAb to even ~60 ng immobilized antigen (Figure 1A).

If mAbs are to be used in therapy, they should bind to antigen in solution phase. Inhibition ELISA was therefore performed. As can be seen in Figure 1B, free antigen was able to compete out the binding of the mAbs to the immobilised antigen in a concentration-dependent manner in case of mAbs C1, C2, C7 and C8 (data not shown for the other mAbs). Therefore, the four mAbs were selected for further studies. Subclass isotyping studies revealed mAbs C1, C2 and C7 to be of IgG1 isotype while C8 was IgG2a. In addition, immunoblot analysis of all 4 antibodies revealed binding of the mAbs also to denatured/linear hTNF α . The experiment was carried out using two concentrations of hTNF α (100 and 500 ng). mAbs are capable of detecting 500 ng of denatured hTNF α and a faint band was detected at the lower concentration (Figure S1E).

A



B




Figure 1

Figure 1 A) Dilution curves of anti-TNF α mAbs. Different concentrations of hTNF α were coated in ELISA plate wells, followed by 2 hr incubation with serially double diluted hybridoma culture supernatants, and subsequently with the secondary antibody for 45 min. The binding of the antibodies was measured by incubation with the secondary antibody conjugated to HRP, followed by incubation with the substrate, TMB H $_2$ O $_2$. The reaction was stopped with H $_2$ SO $_4$ and the absorbance was measured at 450 nm using an ELISA microplate reader. **B)** Inhibition ELISA curves of anti-TNF α mAbs. 500ng of human-TNF α was coated in ELISA wells, followed by addition of free antigen hTNF α (serial double dilution from 5 μ g to 0.0097 μ g) and simultaneously incubated with

pre-determined dilution of the mAbs for 2 hr followed by incubation with anti-mouse Ig conjugated to HRP and the procedure followed as described above.

MAb C8 protects cells from TNF α -mediated toxicity

Several studies have shown that TNF α induces cell death in L929 cells via binding to TNF α R [16]. To determine the activity of our purified recombinant hTNF α protein, L929 cells were subjected to different concentrations of hTNF α , and at 48 hours post-treatment the cell viability was examined using MTT assay. A concentration-dependent cell toxicity was observed and the IC₅₀ (concentration at which there was 50% cell death) was determined to be 6.25 ng /ml (Figure 2A). To confirm that the toxicity seen in L929 cells was indeed because of TNF α , cells were challenged with heat-inactivated hTNF α protein which had no effect on the cell viability (data not shown).

After establishing that recombinant hTNF α was active, the ability of purified anti-TNF α mAbs to rescue cells from TNF α -mediated cytotoxicity was carried out. All 4 mAbs (C1, C2, C7 and C8) rescued L929 cells (Figure 2B), and as can be seen from figures 2C, 2D and S3 supplementary figure the rescue was dose-dependent. Of interest was the mAb C8, which rescued 50% of the cells from hTNF α triggered cytotoxicity at 0.07 μ g/ml and exhibited significant rescue even at 0.017 μ g per ml (Figure 2D).




Figure 2

Figure 2 A) Assessment of human-TNFα activity by MTT assay. L929 cells were incubated with different concentrations of hTNFα. After 48 hr incubation, MTT was added and further incubated for 4 hr. Formazan crystals formed were dissolved in DMSO and OD measured at 570 nm. Actinomycin D (ActD) was used as a positive control. **B)** Rescue from TNF-mediated toxicity with mAbs. L929 cells were incubated with 10 ng/ml hTNFα protein along with anti-TNFα purified antibodies at 100-fold molar excess. MTT assay was performed for cell viability analysis after 48 hr incubation. **C, D)** Rescue of cells from TNF-mediated cell death by mAbs. L929 cells were treated with 10ng/ml hTNFα protein along with the indicated different concentrations of anti-TNFα antibodies starting from 9 μg which is 100-fold molar excess. MTT assay was performed for cell viability analysis after 48 hr incubation. C and D showed mAbs C1 and C8 dose-dependent rescue assay respectively. n = 3 independent experiments, * p<0.05, *** p<0.001.

Comparison of mAb C8 and Infliximab (anti-TNFα mAb)

Infliximab is a chimeric monoclonal antibody developed against TNFα and approved by the U.S. Food and Drug Administration (FDA) for the treatment of autoimmune disease [17]. To compare mAb C8 and Infliximab, indirect ELISA was carried out to study the binding of the mAbs to different

concentrations of hTNF α antigen (Figure 3A). The result revealed that not only in antigen dilution but also in antibody dilution assay, binding of C8 to TNF α is highly comparable with that of infliximab. Both mAbs were found to have high titer as determined by the dilution curves (Figure S 4). Moreover, the binding affinity of the mAbs to immobilized hTNF α was measured using the chaotrope ammonium thiocyanate ELISA to determine relative affinities of mAbs. As presented in Figure 3B the data demonstrate that the affinity of C8 and infliximab are very similar. Importantly, even the L929 cell assay showed that TNF α -mediated cytotoxicity could be rescued by mAb C8 as efficiently as Infliximab (Figure 3C).




Figure 3 A) Comparison of Antibody affinity. Different concentration of hTNF α was coated (x-axis) on ELISA plate, followed by 2hr incubation mAbs with C8 or infliximab. The binding of the antibodies was measured by incubation with the secondary antibody conjugated to HRP, followed by

incubation with the substrate, TMB H_2O_2 . The reaction was stopped with H_2SO_4 and the absorbance was measured at 450 nm using an ELISA microplate reader. light green: mAb C8; dark green: Infliximab. **B)** Comparison of Antibody affinity using ammonium thiocyanate. 500 ng of hTNF α was coated in an ELISA plate followed by 2hr incubation with mAbs, followed by incubation with different concentrations of NH_4SCN in 0.1 M sodium phosphate buffer pH 6.0 for 15 minutes and then secondary antibody conjugated to HRP. **C)** Rescue of cells from TNF α -mediated cytotoxicity. L929 cells were treated with 10 ng/ml hTNF α along with the indicated concentrations of mAb C8 or Infliximab. MTT assay was performed to measure cell viability after 48 hr incubation. Actinomycin-D used as a positive control.

Effect of mAb C8 on TNF α -induced signaling

TNF α mediated cell death has been shown through activation of c-Jun N-terminal kinase (JNK) [18]. TNF α triggers rapid phosphorylation of JNK and sustained JNK activation leads to cell death [19]. To confirm this, L929 cells were treated with different concentrations of TNF α and JNK phosphorylation was assessed with Western blotting. The result shows increase in JNK phosphorylation in a dose-dependent manner in TNF α treated cells, whereas heat-inactivated TNF α failed to show this (Figure 4A). To test whether mAb C8 can inhibit TNF α -mediated JNK activation, we exposed L929 cells with TNF α incubated with C8 or infliximab or mAb C12, following which pJNK level was assessed. As the immunoblot analysis suggests, though mAb C12 had no effect, mAbs C8 and Infliximab inhibited TNF α -mediated JNK phosphorylation. Interestingly, mAb C8 treated cells showed better inhibition as compared to the Infliximab treated cells (Figure 4B).




Figure 4

Figure 4 Immunoblot analysis of TNF α -induced JNK phosphorylation. L929 cells were treated with TNF α alone or along with antibodies for 15 minutes, followed by cell lysis. Cell lysates were electrophoresed on a 10% polyacrylamide gel under denaturing and reducing conditions. Proteins were transferred from the gel to nitrocellulose membrane, probed with pJNK, JNK and actin antibodies, followed by incubation with secondary antibody-HRP conjugate and visualized with ECL

- kit **A)** Cells were incubated with different concentration of TNF α as active and heat inactive forms.
B) Cells were pre-incubated with 10ng/ml TNF α along with mAbs C8/ Infliximab/ C12 or D6F10.

Localization of mAb C8 core epitope

Identification and characterization of the binding sites of neutralizing antibodies might help in the development of new vaccine, diagnostics and therapeutics [20]. Epitope mapping provides insights into the therapeutic mechanism of an individual mAb [21]. To identify the epitope corresponding to mAb C8, we made three overlapping truncated hTNF α fragments F1, F2 and F3 as GST-fusion proteins. MAb C8 bound to full length hTNF α (His-tag fusion 17 KDa) and hTNF α fragment 2 (26-131 aa) proteins but not to F1 (1-53 aa) and F3 (96-157 aa) (Figure 5A). The result was supported by indirect ELISA using different concentration of the fragments incubated with mAb C8 (Figure S 5A). The data suggest that the epitope of mAb C8 lies in TNF α fragment 2 region comprising of amino acid 26-131. Indeed F2 in solution phase bound and competed out the binding of mAb C8 to full length hTNF α as well (Data not shown).

In order to narrow down the epitope corresponding to the mAb C8 further, two truncated constructs were generated from the F2 region of hTNF α , F2 core region (54-93) excluding F1 and F3 overlap and F2-F1 (72-131). MAb bound to F2-F1 (72-131) but not to F2 Core region (54-93) (Figure 5B). The immunoblot study was confirmed by ELISA result as well (Figure S 5C).

Then, 3 overlap fragment constructs were generated from F2-F1 (72-131) region, corresponding to R1 (72-107), R2 (99-131) and R3 (85-120), as GST-fusion proteins. The antibody bound to R2 and R3 but not to R1 (Figure 5C)

Based on mAb C8 binding interaction with both R2 and R3, it is clear that the overlap region of R2 and R3 contained the core epitope of mAb C8, spanning amino acids 99-120 of hTNF α . As observed in Figure S 2A, mAb C8 binding to hTNF α is specific and there is no cross-reactivity of mAb C8 to mTNF α . In the region 99-120 of hTNF α , four amino acids were found to be different between hTNF α and mTNF α . Therefore 3 residues in this stretch were mutated to the corresponding amino acids present in mTNF α , (Q102 R103 E104 to PKD); both 99-120 WT and 99-120 triple mutants' protein constructs were generated. The binding of mAb C8 to 99-120 WT and 99-120 QRE/PKD mutant proteins was analyzed. As shown in immunoblot Figure 5E and ELISA (Figure S 5D) the mAb did not bind to the triple mutated fragment, thereby showing clearly that amino acids Q102 R103 E104 are crucial for the binding of mAb C8 to hTNF α . A schematic diagram of truncated fragments is shown in Figure 5F.




Figure 5 **A)** Immunoblot analysis by ECL of the truncated protein fragments with mAb C8; fragment1 (1-53), fragment2 (26-131), fragment 3 (96-157) and full length hTNFα. 1μg of each purified protein was electrophoresed on a 12.5% polyacrylamide gel under denaturing condition. Proteins were transferred to nitrocellulose membrane, probed with mAb C8 and developed using the ECL kit (Millipore). Lanes: 1: fragment 1; 2: fragment 2; 3: fragment 3; 4: full length hTNFα. **B)** Immunoblot analysis of the truncated protein fragments; full length hTNFα, F1, F2, F2 Core region (54-93) and F2-F1 (72-131). Lanes: 1: full length hTNFα; 2: F1; 3: F2; 4: F2 Core region; 5: F2 (-F1). **C)** Immunoblot analysis of truncated protein fragments; R1 (72-107), R2 (99-131) and R3 (85-120) with mAb C8. The induced samples were electrophoresed on polyacrylamide gel and transferred to nitrocellulose membrane, probed with mAb C8 anti-TNFα antibody and developed. Lanes: 1: R1; 2: R2; 3: R3. **D)** Coomassie stained gel showing purified hTNFα protein and truncated fragments. Lanes: 1: full length hTNFα; 2: F1; 3: F2; 4: F3; 5: 99-120 WT; 6: 99-120 QRE/PKD; M: Molecular weight markers. **E)** Epitope localization of mAb C8. Immunoblot analysis of full length hTNFα and truncated protein fragments; fragment1, fragment2, fragment 3, 99-120 WT and 99-120 QRE/PKD mutants. Lanes: 1: full length hTNFα; 2: fragment 1; 3: fragment 2; 4: fragment 3;

5: 99-120 WT; 6: 99-120 QRE/PKD. (Full length hTNF α is His-fused protein; all truncated and mutated fragments are GST-fused). **F)** Schematic representation of hTNF α constructs F1, F2, F3, F2-F1, Core F2, R1, R2, R3 and 99-120. Truncated gene fragments were generated, cloned in pGEX5X2 vector and expressed *E. coli* BL21 (DE3) competent cells.

Simulation studies revealed that, Infliximab blocks TNF α activity due to binding to the E-F loop of the hTNF α structure, which hampers TNF α -receptor binding. Our study also showed that mAb C8 binds to the E-F loop in the vicinity of Infliximab epitope. This suggests that the C8 binding to TNF α being comparable with Infliximab might be due to juxtaposed epitopes (Figure 6A).

Docking

Docking study was performed by utilizing structural models based on confirmed sequences of the variable regions of heavy (VH) and light (VL) chains of mAb C8 which were generated from RNA isolated from hybridoma cells (Figure 6B). The docking analysis revealed that glutamine at the 102nd position of TNF α interacts with an arginine residue at the 36th position of the light chain of mAb C8. This interaction is crucial to make antigen-antibody induced-fit correctly due to at least two reasons. Firstly, Q102 to P mutation disrupted hydrogen bond between Q-102 (on TNF α) and R-36 (on the antibody light chain). Secondly, the introduction of a proline slightly altered the conformation of the QRE loop, reducing the fit for multiple residues along the binding-loop on TNF α . This conformational change disturbed TNF α -antibody binding (Figure 6C and 6D). Finally, local docking was performed and Rosetta energy score differences were calculated for both WT TNF-Ab as well as mutated TNF-Ab complexes. The entire mutated TNF-Ab complex score is more unfavorable energetically than WT TNF-Ab complex, indicating a disruption in antibody recognition (Figure 6E).




Figure 6

Figure 6 **A)** Ribbon diagram of hTNFα marking the epitopes corresponding to mAbs C8 and Infliximab (in E-F loops of TNFα). Gln102, Arg103 and Glu104 indicated in blue for mAb C8 and Thr 105, Glu107, Ala 109 and Glu110 indicated in red for Infliximab core epitopes. **B)** Schematic representation of the epitope corresponding to mAb C8 in antigen-antibody complex. The core epitopic region (red) of mAb C8 is depicted on the surface of hTNFα (green), mAb C8 heavy and light chains depicted by brown and yellow respectively. **C)** Detailed hTNFα-C8 mAb interface. C8 and hTNFα complex are presented as ribbon diagrams. The Q102 residue that are involved in the intermolecular interaction with R36 residue in light chain of antibody. (epitopic region: red and blue; hTNFα: green; C8 heavy and light chains: brown and yellow respectively). **D)** Triple mutation

introduced in epitopic region Q102R103E104 to PKD, disturbed C8 and hTNF α interaction. The images were generated using open-source PyMOL software. **E)** Comparison of Rosetta energy scores for binding of wild-type (QRE) or mutated (PKD) hTNF α with mAb C8.

Discussion


TNF α is one of the most important pro-inflammatory cytokines which regulates a number of cellular processes like cell proliferation, differentiation and apoptosis [22]. Excessive production of TNF α however is detrimental to health and needs to be regulated. Specific antibodies to TNF α have proven to be useful blockers of TNF α -mediated toxicity. As it is known, anti-TNF α agents bound to TNF α may block interaction between TNF α and its receptors, thus, basically inhibit TNF α -mediated pro-inflammatory signal activation [23, 24].

Even though there are a number of anti-TNF α agents in the market, there is a demand for more TNF α specific antibodies. Like Infliximab, Adalimumab and Etanercept are currently being used in the alleviation of inflammatory immune disorders via interruption of TNF α -TNFR interaction [25]. Infliximab was the first approved anti-TNF α drug for the management of autoimmune conditions such as Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and various inflammatory skin problems [26, 27].

In our study, we found mAb C8 to bind with high affinity to TNF α . Since hTNF α -mediated cell death in L929 fibroblast cells is a well-accepted cell culture model [16], we utilized it to test the rescue from cytotoxicity by our panel of mAbs. MAb C8 inhibited TNF α -mediated activity significantly and comparable with that of Infliximab. Due to specificity of mAb C8 to human-TNF α only, we could not test the effect of mAb C8 in blocking the biological activity of TNF α in a mouse model. However, comparable cell rescue from TNF α -mediated toxicity and inhibition of TNF α -mediated signaling by both antibodies may suggest the capability of mAb C8 in blocking the physiological activity of TNF α also *in-vivo*. That mAb C8 inhibits TNF α -induced cell signaling was also demonstrated by assessing the decrease in activation of JNK.


In order to get insights into the mechanism by which C8 antibody inhibits hTNF α -mediated toxicity, we initiated studies to identify the epitope corresponding to the mAb. The core epitope of mAb C8 was delineated to amino acid sequence 99-120. Mutational analysis in this region established unequivocally that residues Gln102, Arg103 and Glu104 are the most critical for binding of mAb C8 to hTNF α . It is worth mentioning that, these residues are located in the EF loop of TNF α structure. Interestingly, the epitope of Infliximab on TNF α structure comprises of the C-D and E-F loop and include residues Glu67-His73 and Thr105-Lys112 respectively, as well as several residues in C and D strands and blocks its activity. MAb C8 and Infliximab binding to the EF loop hampers TNF α binding to its receptor, as a result inhibits its activity.

In conclusion, we have established a mAb with the ability to neutralize hTNF α at the same efficiency as Infliximab, therefore could be explored for clinical application.




Supplementary Figure 1

S-Figure 1 A) Purification of His-tagged hTNFα. Transformed *E.coli* cells induced for the expression of hTNFα were lysed and the supernatant was loaded on Ni-NTA column. The bound protein was eluted with 300 mM Imidazole in TBS. The fractions were electrophoresed on a 12.5% polyacrylamide gel under reducing conditions and stained with Coomassie brilliant blue. Lanes: 1: Load; 2: flow through; 3-5: washes; 6-14: elutions; M: Molecular weight markers. **B)** Mass spectrometry of purified recombinant human-TNFα deconvoluted peak. **C)** Indirect ELISA to study hTNFα -mAb. hTNFα was coated in the wells of ELISA plate at 1μg per well and incubated with 100 μl of hybridoma culture supernatants for 2hr, followed by incubation with anti-mouse Ig conjugated to HRP. Binding was assessed by adding the substrate and absorbance of the product was measured at 450 nm using an ELISA microplate reader. n = 3 independent experiments. **D)** Indirect ELISA to study mTNFα - mAb interaction. 1μg per well mTNFα was coated, followed by 2hr incubation with 100 μl of hybridoma culture supernatants, followed by the procedures as explained in part C. SP20: negative control. n = 3 independent experiments.



Supplementary Figure 2

S-Figure 2 A) Determination of sensitivity of mAbs to human-TNFα. 100 and 500 ng human-TNFα protein (lane 1 and 2 respectively) were electrophoresed on a 12.5% polyacrylamide gel under denaturing condition. Protein was transferred from the gel on to nitrocellulose membrane, probed with C1, C2, C7 and C8 anti-TNFα monoclonal antibodies and developed using the ECL kit (Millipore), $n = 3$ independent experiments. **B, C)** mAbs C2 and C7 can rescue cells from TNF-mediated cell death in dose-dependent manner. L929 cells were treated with 10 ng/ml human-TNFα protein along with the indicated different doses of anti-TNFα antibodies starting from 9 μg which is 100-fold molar excess. MTT assay was performed for cell viability analysis after 48 hr incubation. B and C showed anti TNF-α antibody C2, C7 dose-dependent rescue assay respectively. Actinomycin D used as a positive control. **D)** Dilution curves of C8 and Infliximab anti-TNFα mAbs. 200 ng of hTNFα was coated, followed by 2 hr incubation with dilutions of mAbs'. Absorbance was measured at 450 nm using an ELISA microplate reader.



Supplementary Figure 3

S-Figure 3 A) Indirect ELISA for binding of mAbs to different concentrations of hTNFα truncated overlapping constructs. The extent of binding of mAb C8 to immobilized fragment1 (1-53), fragment2 (26-131), fragment 3 (96-157) and full length hTNFα was determined. 2, 1 and 0.5 µg per well of each protein were coated, followed by 2hr incubation with 100 µl of mAb culture supernatant. The rest of the procedure followed was as mentioned in the legend of figure S 1C. mAb C2 used for antibody interaction comparison. **B)** Indirect ELISA of fragment2 (26-131) mutants with mAb C8. The extent of binding of the antibody to immobilized full length TNFα, F1,F2,F3 and F2

mutants T72D; H73Y; T89E; S71del; TH72,73DY; Q102P; R103K; E104D; RE103,104KD; R131Q were determined. There are indications below x-axis which show that mutants introduced in F2 background and in F2 S71 del, H73Y background. **C)** Binding of mAb C8 and hTNF α truncated constructs using Indirect ELISA. The extent of binding of the antibody to immobilized full length hTNF α , F1, F2, F3, F2 Core region (54-93) and F2-F1 (72-131) were determined. **D)** Epitope localization of mAb C8. The extent of binding of the antibody to immobilized full length hTNF α , F1, F2, F3, 99-120 WT and 99-120 QRE/PKD mutants was determined. For sections B, C and D, 1 μ g per well of each protein were coated, followed by 2h incubation with 100 μ l of mAb culture supernatant.

Acknowledgements

We thank the Central Animal Facility, Indian Institute of Science (IISc). We thank Dr. Manjula Das and Dr. Akanksha Dixit for valuable discussions and critical comments. We greatly acknowledge financial support from the Department of Biotechnology, DBT-IISc partnership program. We also thank IISc-student fellowship support.

References

- Tracey, K.J. and A. Cerami, *Tumor necrosis factor: a pleiotropic cytokine and therapeutic target*. Annu Rev Med, 1994. **45**: p. 491-503.
- Baxter, G.T., et al., *Tumor necrosis factor-alpha mediates both apoptotic cell death and cell proliferation in a human hematopoietic cell line dependent on mitotic activity and receptor subtype expression*. J Biol Chem, 1999. **274**(14): p. 9539-47.
- Clark, I.A., et al., *Possible importance of macrophage-derived mediators in acute malaria*. Infect Immun, 1981. **32**(3): p. 1058-66.
- van der Bruggen, T., et al., *Lipopolysaccharide-induced tumor necrosis factor alpha production by human monocytes involves the raf-1/MEK1-MEK2/ERK1-ERK2 pathway*. Infect Immun, 1999. **67**(8): p. 3824-9.
- Kircheis, R., et al., *Differences in the biological activity of TNF alpha and TNF beta correlate with their different abilities for binding to the target cells*. Eur Cytokine Netw, 1992. **3**(4): p. 381-90.
- Loetscher, H., et al., *Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor*. Cell, 1990. **61**(2): p. 351-9.
- Tartaglia, L.A. and D.V. Goeddel, *Two TNF receptors*. Immunol Today, 1992. **13**(5): p. 151-3.
- Aggarwal, B.B., S.C. Gupta, and J.H. Kim, *Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey*. Blood, 2012. **119**(3): p. 651-65.
- MacEwan, D.J., *TNF receptor subtype signalling: differences and cellular consequences*. Cell Signal, 2002. **14**(6): p. 477-92.
- Peyrin-Biroulet, L., *Anti-TNF therapy in inflammatory bowel diseases: a huge review*. Minerva Gastroenterol Dietol, 2010. **56**(2): p. 233-43.
- Ma, X. and S. Xu, *TNF inhibitor therapy for rheumatoid arthritis*. Biomed Rep, 2013. **1**(2): p. 177-184.

12. Ho, S.N., et al., *Site-directed mutagenesis by overlap extension using the polymerase chain reaction*. Gene, 1989. **77**(1): p. 51-9.
13. Schwede, T., et al., *SWISS-MODEL: An automated protein homology-modeling server*. Nucleic Acids Res, 2003. **31**(13): p. 3381-5.
14. Konagurthu, A.S., et al., *MUSTANG: a multiple structural alignment algorithm*. Proteins, 2006. **64**(3): p. 559-74.
15. Gray, J.J., et al., *Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations*. J Mol Biol, 2003. **331**(1): p. 281-99.
16. Humphreys, D.T. and M.R. Wilson, *Modes of L929 cell death induced by TNF-alpha and other cytotoxic agents*. Cytokine, 1999. **11**(10): p. 773-82.
17. Monaco, C., et al., *Anti-TNF therapy: past, present and future*. Int Immunol, 2015. **27**(1): p. 55-62.
18. Dietrich, N., et al., *JNK2 mediates TNF-induced cell death in mouse embryonic fibroblasts via regulation of both caspase and cathepsin protease pathways*. Cell Death Differ, 2004. **11**(3): p. 301-13.
19. Barbin, G., M.P. Roisin, and B. Zalc, *Tumor necrosis factor alpha activates the phosphorylation of ERK, SAPK/JNK, and P38 kinase in primary cultures of neurons*. Neurochem Res, 2001. **26**(2): p. 107-12.
20. Gershoni, J.M., et al., *Epitope mapping: the first step in developing epitope-based vaccines*. BioDrugs, 2007. **21**(3): p. 145-56.
21. Hasan, S.S., et al., *A human antibody against Zika virus crosslinks the E protein to prevent infection*. Nat Commun, 2017. **8**: p. 14722.
22. Liu, Z.G., *Molecular mechanism of TNF signaling and beyond*. Cell Res, 2005. **15**(1): p. 24-7.
23. Wong, M., et al., *TNFalpha blockade in human diseases: mechanisms and future directions*. Clin Immunol, 2008. **126**(2): p. 121-36.
24. Sedger, L.M. and M.F. McDermott, *TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future*. Cytokine Growth Factor Rev, 2014. **25**(4): p. 453-72.
25. Mukai, Y., et al., *Solution of the structure of the TNF-TNFR2 complex*. Sci Signal, 2010. **3**(148): p. ra83.
26. Buch, M.H., et al., *True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?* Ann Rheum Dis, 2004. **63**(10): p. 1344-6.
27. Liang, S., et al., *Structural basis for treating tumor necrosis factor alpha (TNFalpha)-associated diseases with the therapeutic antibody infliximab*. J Biol Chem, 2013. **288**(19): p. 13799-807.